Top Markets
#1 Purr Purr +63.76%
#2 Pons Pons +51.76%
#3 Smilek to the Bank Smilek to the Bank +50.56%
#4 Non-Playable Coin Non-Playable Coin +34.60%
#5 ApeX ApeX +29.89%
#6 Kinetiq Kinetiq +27.29%
#7 Morpho Morpho +24.45%
#8 StonkBroker StonkBroker +23.94%
#9 Cash Cat Cash Cat +23.07%
#10 OriginTrail OriginTrail +21.94%
Coin of the day
Purr Purr
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
NGM Biopharmaceuticals, Inc. NGM Biopharmaceuticals, Inc.

NGM Biopharmaceuticals, Inc.

NGM
Classement en actions #20909
NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering... NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering and developing innovative therapies for liver and metabolic ailments, retinal conditions, and various forms of cancer. The company's advanced product candidates include Aldafermin, a modified version of the human hormone fibroblast growth factor 19, which is currently undergoing Phase IIb clinical evaluation for non-alcoholic steatohepatitis (NASH). Another key asset, MK-3655, is an agonistic antibody designed to activate fibroblast growth factor receptor 1c-beta-klotho, also in Phase IIb trials for treating both type 2 diabetes and NASH. NGM's pipeline further encompasses NGM120, an antagonist antibody targeting GFRAL, in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II development for geographic atrophy; and NGM707, a dual antagonist monoclonal antibody (targeting immunoglobulin-like transcript 2/4) in Phase I/II trials for patients with advanced solid tumors. Additionally, the company is developing NGM831 and NGM438, both intended for the treatment of advanced solid tumors. NGM has established significant partnerships, including research, product development, and licensing agreements with Merck Sharp & Dohme Corp. A separate collaboration with Merck & Co., Inc. is dedicated primarily to creating new treatments for pressing unmet patient needs in retinal and cardiovascular-metabolic (CVM) diseases, such as heart failure. Established in 2007, NGM Biopharmaceuticals, Inc. maintains its corporate headquarters in South San Francisco, California.
Prix de l'action
$1.54
Dernière synchronisation: 2024-04-08
Capitalisation boursière
$119.21M
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange NGM Biopharmaceuticals, Inc. (NGM)

Catégorie

Healthcare
Le prix NGM avec la capitalisation boursière de B
NGM Biopharmaceuticals, Inc. NGM Biopharmaceuticals, Inc.
NGM
$1.54
Capitalisation boursière de NGM Biopharmaceuticals, Inc.(NGM)
Capitalisation boursière: $119.21M
En August 2026, NGM Biopharmaceuticals, Inc. a une capitalisation boursière de $119.21M. Cela fait de NGM Biopharmaceuticals, Inc. la 20909th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de NGM Biopharmaceuticals, Inc. du 2019 au 2026
NGM par rapport au top 5 des plus populaires stocks
Prix pour NGM L’actif B La capitalisation boursière de B Résultats
NGM Biopharmaceuticals, Inc. NGM Biopharmaceuticals, Inc.
$67,322.89 $119.21M
NVIDIA Corporation NVIDIA Corporation
NVDA
$5.211T +4,371,516.28%
NGM Biopharmaceuticals, Inc. NGM Biopharmaceuticals, Inc.
$58,736.98 $119.21M
Apple Inc. Apple Inc.
AAPL
$4.547T +3,813,989.78%
NGM Biopharmaceuticals, Inc. NGM Biopharmaceuticals, Inc.
$53,772.80 $119.21M
Alphabet Inc. Alphabet Inc.
GOOG
$4.162T +3,491,640.48%
NGM Biopharmaceuticals, Inc. NGM Biopharmaceuticals, Inc.
$46,413.34 $119.21M
Microsoft Corporation Microsoft Corporation
MSFT
$3.593T +3,013,753.51%
NGM Biopharmaceuticals, Inc. NGM Biopharmaceuticals, Inc.
$36,079.39 $119.21M
Amazon.com, Inc. Amazon.com, Inc.
AMZN
$2.793T +2,342,717.73%